Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozanimod (Zeposia) In Patients With RRMS: A 5-Year, Multicenter, Prospective, Non-Interventional Study to Document Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany (OZEAN)

Next Previous
Trial Profile

Ozanimod (Zeposia) In Patients With RRMS: A 5-Year, Multicenter, Prospective, Non-Interventional Study to Document Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany (OZEAN)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms OZEAN
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 08 Sep 2025 Status changed from active, no longer recruiting to completed.
  • 30 Sep 2024 Planned End Date changed from 30 Nov 2027 to 30 Nov 2029.
  • 30 Sep 2024 Planned primary completion date changed from 1 Mar 2027 to 31 Mar 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top